Vivesto

0,229

SEK

-2,35 %

Mindre end 1K følgere

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-2,35%

-1,51%

-0,43%

-21,03%

-14,39%

-23,67%

-78,19%

-96,74%

-98,73%

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious oncology diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1988 and is headquartered in Uppsala, Sweden.

Markedsværdi

123,21 mio. SEK

Aktieomsætning

41,66 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

12.8

2025

Delårsrapport Q2'25

11.11

2025

Delårsrapport Q3'25

12.2

2026

Årsrapport '25

Alle

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelse8.5.2025, 16.53

Carnegie Access: Vivesto: Paccal Vet data expected this summer – Q1(25) review

Selskabsmeddelelse8.5.2025, 08.30

Report from Annual General Meeting in Vivesto AB

Selskabsmeddelelse8.4.2025, 06.00

Notice of Annual General Meeting in Vivesto AB

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse1.4.2025, 06.00

Vivesto reports positive Cantrixil results in an animal hematological cancer model

Pressemeddelelse31.3.2025, 15.11

Carnegie Access: Vivesto: Secures the full rights to Cantrixil

Selskabsmeddelelse31.3.2025, 06.00

Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights

Pressemeddelelse18.3.2025, 11.08

Carnegie Access: Vivesto: Licensing deal for Apealea announced with Zhida

Selskabsmeddelelse18.3.2025, 06.15

Vivesto licenses Apealea to China’s Zhida Pharmaceutical

Pressemeddelelse20.2.2025, 16.10

Carnegie Access: Vivesto: Intervju – Statusuppdatering efter Q4 2024-rapporten

Pressemeddelelse16.1.2025, 13.00

Vivesto receives approval to initiate a dose-finding study of Paccal Vet in cats

Pressemeddelelse19.12.2024, 10.00

Vivesto strengthens Cantrixil program with new preclinical results and patent application

Pressemeddelelse11.11.2024, 10.33

Vivesto’s Paccal Vet receives Limited Market classification in EU

Selskabsmeddelelse7.11.2024, 09.54

Vivesto signs Apealea option agreement with Zhida Pharmaceutical

Pressemeddelelse1.7.2024, 06.00

Vivesto receives positive Cantrixil preclinical efficacy data

Selskabsmeddelelse23.5.2024, 08.48

Report from Annual General Meeting in Vivesto AB

Selskabsmeddelelse23.4.2024, 06.00

Notice of Annual General Meeting in Vivesto AB

Pressemeddelelse19.3.2024, 12.06

Vivesto to hold live-streamed Paccal Vet R&D Update on March 26

Selskabsmeddelelse7.3.2024, 07.10

Vivesto doses first patient in its clinical Paccal Vet trial

Pressemeddelelse30.1.2024, 07.00

Vivesto's international patent application for XR-18 receives positive decision

Pressemeddelelse28.12.2023, 07.00

Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.